{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001559","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2021-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.896090+00:00","generated_at":"2026-06-29T07:53:23.182644+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Caribou Biosciences appoints Nancy Whiting to board of directors","bullets":["Nancy Whiting, Pharm.D., appointed as Class II director effective August 24, 2021.","She receives $40,000 annual cash retainer plus $5,000 for compensation committee service.","Dr. Whiting brings over 17 years of biotech experience, most recently as EVP at Seagen Inc.","Her oncology drug development expertise aligns with Caribou's pipeline of allogeneic cell therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001559","json":"https://secwatch.observer/filing/0000950170-21-001559.json","markdown":"https://secwatch.observer/filing/0000950170-21-001559.md","text":"https://secwatch.observer/filing/0000950170-21-001559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/0000950170-21-001559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/crbu-20210824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T07:53:23.182644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09130b2d16","claim":"Nancy C. Whiting was appointed as Director at Caribou Biosciences, Inc..","evidence_excerpt":"unanimously agreed to extend an offer to Nancy C. Whiting, Pharm. D. to serve as a Class II director of the Company, which offer Dr. Whiting accepted on August 24, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/0000950170-21-001559-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}